Kyowa Kirin invests $530M in first manufacturing site in North America

Kyowa Kirin is investing $530 million into a 171,700 square-foot manufacturing facility in Sanford, North Carolina, which will make biologic therapies, including antibodies, for clinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pharmalittle: We’re reading about a former Trump FDA chief criticizing RFK Jr., a radiopharmaceuticals talent shortage, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was extended for many on our side of the

December 2, 2024

FDA approves AstraZeneca’s Imfinzi for LS-SCLC treatment

The FDA also granted breakthrough status to AstraZeneca’s Imfinzi for LS-SCLC treatment. Credit: © AstraZeneca 2024. The US Food and Drug Administration (FDA) has approved

December 5, 2024

Teva, Sanofi conclude collaboration deal for anti TL1A therapy

Share this article TEV ‘574 is under assessment in Phase IIb clinical studies to treat ulcerative colitis and Crohn’s disease. Credit: sdecorated / Shutterstock.com. Teva

December 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.